Galapagos
- Country
- ๐ง๐ชBelgium
- Ownership
- Public
- Established
- 1999-01-01
- Employees
- 1.1K
- Market Cap
- $1.9B
- Website
- http://www.glpg.com
- Introduction
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis
- First Posted Date
- 2019-06-06
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 31
- Registration Number
- NCT03976648
- Locations
- ๐ง๐ช
UZ Gent, Gent, Belgium
๐ช๐ธHospital Universitario Vall d'Hebron, Barcelona, Spain
๐ฌ๐งRoyal Free Hospital, London, United Kingdom
Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis
- Conditions
- Rheumatoid ArthritisPsoriatic ArthritisAnkylosing SpondylitisNon-Radiographical Axial Spondyloarthritis
- Interventions
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 109
- Registration Number
- NCT03926195
- Locations
- ๐ง๐ฌ
DCC 17 - Sofia EOOD, Sofia, Bulgaria
๐ง๐ฌUMHAT Sv. Georgi, EAD, Plovdiv, Bulgaria
๐ง๐ฌMHAT "Eurohospital" - Plovdiv, OOD, Plovdiv, Bulgaria
A Study to Evaluate the Effects of a Single and Multiple Oral Doses of GLPG3121 in Adult, Healthy, Male Subjects
- Conditions
- Healthy
- Interventions
- Drug: Placebo SADDrug: GLPG3121 SADDrug: GLPG3121 MADDrug: Placebo MAD
- First Posted Date
- 2019-04-02
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 31
- Registration Number
- NCT03899909
- Locations
- ๐ง๐ช
SGS Belgium NV - Clinical Pharmacology Unit Antwerp, Antwerp, Belgium
A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2019-03-06
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 33
- Registration Number
- NCT03864627
- Locations
- ๐บ๐ธ
Advanced Research Institute of Miami LLC, Homestead, Florida, United States
๐บ๐ธMarvel Research, LLC, Huntington Beach, California, United States
๐บ๐ธArlington Dermatology, Rolling Meadows, Illinois, United States
A Study Investigating the Safety, Absorption and Elimination of GLPG3312, a New Drug in the Treatment of Inflammatory Diseases
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 95
- Registration Number
- NCT03800472
- Locations
- ๐ณ๐ฑ
PRA Health Sciences, Groningen, Netherlands
A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis
- First Posted Date
- 2019-01-09
- Last Posted Date
- 2021-05-04
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 33
- Registration Number
- NCT03798366
- Locations
- ๐บ๐ธ
Massachusetts General Hospital, Boston, Massachusetts, United States
๐บ๐ธPacific Arthritis Care Center, Los Angeles, California, United States
๐บ๐ธRASF Clinical Research Center, Boca Raton, Florida, United States
A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Given by Mouth and Into a Vein as an Injection
- Conditions
- Healthy
- Interventions
- Drug: GLPG1690 film-coated tabletsDrug: [14C]-GLPG1690 capsulesDrug: [14C]-GLPG1690 solution for infusion
- First Posted Date
- 2018-12-26
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 8
- Registration Number
- NCT03787186
- Locations
- ๐ฌ๐ง
Quotient Sciences Limited, Ruddington, United Kingdom
A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 781
- Registration Number
- NCT03733444
- Locations
- ๐บ๐ธ
St. Francis Medical Institute, Clearwater, Florida, United States
๐บ๐ธEmory University, Atlanta, Georgia, United States
๐บ๐ธPiedmont Healthcare, Atlanta, Georgia, United States
A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2018-10-31
- Last Posted Date
- 2021-09-14
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 68
- Registration Number
- NCT03725852
- Locations
- ๐บ๐ฆ
The Ivano-Frankivsk National Medical Univeristy, Ivano-Frankivs'k, Ukraine
๐บ๐ฆMunicipal Institution "Kherson city clinical hospital named after E.E. Karabelesh", Kherson, Ukraine
๐บ๐ฆOdessa Regional Hospital, Odessa, Ukraine
A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
- First Posted Date
- 2018-10-18
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 525
- Registration Number
- NCT03711162
- Locations
- ๐บ๐ธ
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
๐ฆ๐บFlinders Medical Centre, Bedford Park, Australia
๐ฆ๐บBox Hill Hospital, Box Hill, Australia